Powered by: Motilal Oswal
2025-03-26 04:46:08 pm | Source: JM Financial Services Ltd
Healthcare Sector Update : Growth dips to 4% By JM Financial Services
Healthcare Sector Update : Growth dips to 4% By JM Financial Services

Growth dips to 4%

IPM grew by ~4% YoY in Feb’25 (down from 8.5% in Jan’25), this lags 3Y CAGR of ~8%. It grew 7.4% YoY based on MAT Feb’25, driven by 4% price, ~1% volume and 2% NI growth. In Feb’25, both acute and chronic segment growth were subdued vs Jan’25 levels. Chronic segment grew 5% YoY while acute growth came in at 3% YoY. Therapy outperformers during the month were Urology (+10%), GI (+8%) and Cardiac (+7%). Top performers in the listed universe were P&G Health (+15%), FDC (+14%), IPCA (+11%) and JBCP (+10%). Our coverage outperformers were IPCA, JBCP, ZYDUSLIF, SUNP, CIPLA, and LPC while TRP and DRRD underperformed IPM. We believe that price growth of 4-5%, NI of 2-3% and volume growth of ~1% will drive high single-digit FY25 IPM growth.

 

* IPCA, JBCP, ZYDUSLIF, SUNP, CIPLA, and LPC outperform IPM: Based on Feb’25 IPM data, Sun retained its top spot with ~8% market share (ms). For the same period, Alkem, Glaxo and FDC have improved their rank by 1 each to 5 th, 14th and 22 nd respectively. For the month of Feb’25, our coverage outperformers were IPCA, JBCP, ZYDUSLIF, SUNP, CIPLA, and LPC, delivering 11%/10%/8%/8%/5%/5% YoY growth respectively. TRP and DRRD underperformed the IPM due to weak performance of top therapies (VMN, Pain) for TRP, and (GI, Respi, Pain) for DRRD. We expect chronic-focused players to continue to deliver double-digit growth. Indian companies registered 4.3% growth during the month while MNC’s grew 3.2%.

* Volume growth at ~1% in MAT Feb’25: IPM growth of 7% based on MAT Feb’25 was driven by price growth of 4%, NI growth of 2% and volume growth of just 1%. Unit growth in Feb’25 was negative. CIPLA, IPCA reported positive unit growth this month. Overall, we expect high single-digit growth for IPM in FY25 driven by price growth of 4- 5%, NI of 2-3% and volume growth of 1%.

* Urology, GI outperform: Therapy outperformance was led by Urology and GI which grew 10%/8% respectively. While IPM’s top therapy, Cardiac, grew 7% YoY growth in Feb’25, significantly ahead of the IPM. Chronic and Acute therapies reported 5%/3% YoY growth respectively during the month. Growth was dragged by Gynaec., Anti-infectives and Respiratory. In the Anti-diabetic segment, SUNP reported 14.5% growth, while Abbott reported flat growth. Ipca has consistently outperformed market growth in the Pain segment led by the Zerodol franchise. While Derma growth was a subdued at 3.7% YoY in Feb‘25, DRRD reported 10% growth aided by Venusia. While Cardiac has grown ahead of IPM, SUNP continues to underperform in this segment.

* Feb’25 Top brands’ performance: Electral is claimed No. 1 position in Feb’25 growing 44%. IPCA’s Zerodol-SP gained three ranks and grew 13%. Rybelsus (semaglutide) continued to scale-up with 44% growth. Cipla’s top 10 brands reported 5% YoY growth – Foracort (slipped to the second largest brand in Feb’25) recorded flat growth for the month. Zydus’ Lipaglyn maintained double-digit trajectoryof 85%. IPCA’s Zerodol franchise continued its growth, led by Zerodol-SP (+13% YoY). GLXO’s top brand Augmentin declined 6% YoY, with other key top brands, viz. Calpol, T-bact and Betnovate-N, reporting -7%/+3%/-19% growth respectively. JB Pharma’s Azmarda grew 10% YoY and DRRD’s Cidmus grew 14%. Sun’s growth was driven by steady performance of smaller brands. Sanofi’s Lantus declined 7% YoY (Toujeou grew +6%YoY).

 

 

Please refer disclaimer at https://www.jmfl.com/disclaimer

SEBI Registration Number is INM000010361

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here